Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stopping anti-TNF treatment in Crohn’s and Colitis patients in remission
2016-000235-40Phase 4Active
- Sponsor
- Region Skåne
- Start
- Jun 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4 trial of infliximab and adalimumab in Crohn's disease and autoimmune colitis (2 arms), sponsored by Region Skåne. Primary endpoints: Relapse rate at 12 months and Relapse rate at 24 months. Started Jun 2016; status: active.
02
Drugs
infliximabadalimumab
03
Conditions
Crohn's diseaseautoimmune colitis
Beyond the preview
Go deeper on 2016-000235-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000235-40.